Insight Molecular Diagnostics outlines $2B annual market opportunity and signals rapid commercialization push for GraftAssureDx (NASDAQ:IMDX)

IMDX Q4 2025 earnings call highlights: FDA submission for GraftAssureDx, commercialization plans, cash burn, and heart expansion.

You will be redirected in 10 seconds.

liveinternet liveinternet